Dupilumab-Induced Follicular Conjunctivitis
Authors:
- 18 October 2018
- journal article
- letter
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 27 (8) , 1339-1341
Abstract
(2018). Dupilumab-Induced Follicular Conjunctivitis. Ocular Immunology and Inflammation. Ahead of Print.Keywords
This publication has 10 references indexed in Scilit:
- Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab–clinical characteristics and treatmentThe Journal of Allergy and Clinical Immunology: In Practice, 2018
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical tBritish Journal of Dermatology, 2017
- Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitisJournal of the American Academy of Dermatology, 2017
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- ConjunctivitisJAMA, 2013
- Conjunctiva Immune Surveillance2010
- Conjunctiva-Associated Lymphoid Tissue – Current Knowledge, Animal Models and Experimental ProspectsOphthalmic Research, 2009
- Atopic keratoconjunctivitisOcular Immunology and Inflammation, 1994